Core Viewpoint - A securities class action lawsuit has been filed against BioAge Labs, Inc. for alleged misleading statements related to its IPO and clinical trials [1][2]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased BioAge stock during the IPO on September 26, 2024, with a lead plaintiff deadline set for March 10, 2025 [1]. - Allegations include that BioAge's registration statement and prospectus contained false or misleading statements regarding the STRIDES Phase 2 trial for azelaprag, specifically concerning liver transaminitis and safety concerns [2]. Group 2: Lead Plaintiff Process - Investors can seek to be appointed as a lead plaintiff representative by March 10, 2025, or remain absent class members [3]. - The lead plaintiff will represent the interests of all class members and select counsel for the litigation [3]. Group 3: Law Firm Background - Kessler Topaz Meltzer & Check, LLP has a reputation for prosecuting class actions and has recovered billions for victims of corporate misconduct [4].
BIOA Deadline in 4 Days: Kessler Topaz Meltzer & Check, LLP Reminds BioAge Labs, Inc. (BIOA) Investors of Filing Deadline in Class Action Lawsuit